NEW

GE HealthCare Preps for SIR 2024

GE HealthCare will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, Utah. The...

Samsung Accepts Healthcare Innovator Award

Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound business, was awarded HHM Health’s Healthcare Innovator Award

AHRA Co-Founder Passes Away

On March 2, 2024, Louise Broadley passed away at 101 years old. AHRA shared the news via an email and website post that reads, “She was a noble woman, who not only achieved many milestones within the imaging profession, but likewise paved the way for aspiring leaders...

Artificial Intelligence Paper Outlines FDA’s Approach to Protect Public Health and Promote Ethical Innovation

Today, the U.S. Food and Drug Administration (FDA) released its “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” which outlines how FDA’s medical product centers are working together to protect public health while...

Majority of Canon Medical’s CT Portfolio Now FDA-Cleared for Low-Dose Lung Cancer Screening

Lung cancer is the most common cancer worldwide, accounting for 2.1 million new cases and 1.8 million deaths in 2018.[i] The majority of Canon Medical Systems USA, Inc.’s CT portfolio has received 510(k) clearance for low-dose lung cancer screening (LCS), providing comprehensive offerings to help advance patient care. LCS has been proven to detect lung cancer at earlier stages, when it’s most treatable, as well as reduce mortality by 20 percent compared to standard chest x-ray.[ii]

Canon Medical offers the full range of tools and options customers need to help create an effective LCS program. This holistic approach overcomes the current barriers in adoption with a complete solution that includes:

  • Protocol management: Effectively manage CT dose, protocols and equipment to standardize care and improve quality with Vitality XT.
  • Marketing support: Quick access to co-branded materials available on Canon Medical’s Image Maker platform to help drive referrals and increase awareness.
  • Dose reduction and advanced ergonomics: Industry-leading dose reduction capabilities and ergonomics available on the Aquilion family of CT systems to help increase safety from start to finish.
  • Automatic nodule tracking: Visia™ CT Lung CAD Vitrea CT Lung Analysis tools available to detect lung nodules at an early stage through advanced visualization.
  • Largest PET/CT Bore for treatment planning and monitoring: Canon Medical’s Celestion PET/CT system puts patient comfort first to improve the quality of care for patients.

“Developing a lung cancer screening program is a complex, multi-layered undertaking, and a comprehensive solution is crucial to a program’s success,” said Tim Nicholson, acting managing director, CT and PET/CT Business Unit, Canon Medical Systems USA. “Lung cancer is a leading cause of death in the U.S. and across the world due to the fact that it typically shows little to no symptoms in early stages, where the survival rates are around 45 percent, in contrast to the survival rates by Stage 4, which range from a devastating one to two percent.[iii] Early detection is critical, and we are committed to offering solutions for health care providers that can make a difference in the patient community and beyond.”

[i] World Health Organization. Cancer Fact Sheet, 2018.

[ii] The National Lung Screening Trial research team. Reduced lung cancer mortality with low dose computed tomographic screening. N Engl J Med, 2011; 365:395-409.

[iii] Eldridge, L. Lung cancer survival rates by type and stage. Very Well Health. Accessed June 20, 2019. http://lungcancer.about.com/od/whatislungcancer/a/lungcancersurvivalrates.htm.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

Open